China News Service, May 23, according to Reuters, the United States plans to recruit more than 100,000 volunteers to test about six of the most promising new crown vaccine candidates in order to obtain a safe and effective new crown vaccine by the end of 2020.
Data map: Vaccine. Photo by Tang Yanjun
According to reports, to curb the epidemic of the new coronavirus, the United States will compress vaccine development and testing, which usually takes 10 years to complete, to a few months.
The project's scientists said that in order to achieve this goal, the leading vaccine manufacturers in the research and development process have agreed to share data and lend their clinical trial network to competitors if their own candidate vaccine development fails.
Starting in July, each candidate vaccine that proved safe in a small early study will be tested on 20,000 to 30,000 volunteers.
Larry Corey, a vaccine expert at the Fred Hutchinson Cancer Center in the United States, said there may be 100,000 to 150,000 people involved.
Collins, president of the National Institutes of Health, told Reuters: "If no security problems are found, the research will continue."
It is reported that the vaccine is mainly used by healthy people. The research and development process will usually be tested in steps, first of all animal testing.
Before conducting human trials, a small safety trial should be conducted for healthy volunteers, and then a larger study should be carried out to find the appropriate dosage and understand the efficacy of the vaccine early. The final stage includes large-scale testing of thousands of people. Only after these steps are completed, can the vaccine be mass-produced.
Collins and Corey said that during the new crown epidemic, many of the steps in the above process will overlap, especially in the mid and late trials. The report said that the method adopted by the project is risky because certain safety issues may only appear in large-scale trials.
A survey conducted jointly by Reuters and Ipsos showed that Americans are concerned about the speed of vaccine development.